Cargando…
The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis
BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare myeloid precursor cell inflammatory neoplasia, which agonizes, maims, and even kills patients. Although clinical outcomes have steadily improved over the past decades, the progression/relapse rate of LCH remains high. The purpose of this stud...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498231/ https://www.ncbi.nlm.nih.gov/pubmed/37711802 http://dx.doi.org/10.21037/qims-23-290 |
_version_ | 1785105475344269312 |
---|---|
author | Lu, Xia Wei, Ang Wang, Guanyun Du, Junye Feng, Lijuan Ou, Wenxin Wang, Tianyou Wang, Wei Li, Jixia Zhang, Mingyu Zhang, Rui Yang, Jigang |
author_facet | Lu, Xia Wei, Ang Wang, Guanyun Du, Junye Feng, Lijuan Ou, Wenxin Wang, Tianyou Wang, Wei Li, Jixia Zhang, Mingyu Zhang, Rui Yang, Jigang |
author_sort | Lu, Xia |
collection | PubMed |
description | BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare myeloid precursor cell inflammatory neoplasia, which agonizes, maims, and even kills patients. Although clinical outcomes have steadily improved over the past decades, the progression/relapse rate of LCH remains high. The purpose of this study was to evaluate the prognostic value of the pre-treatment metabolism parameters of baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F‑FDG PET/CT) in children with LCH. METHODS: This cross-sectional study retrospectively and consecutively included 37 children (24 males and 13 females; median age, 5.1 years; range, 2.4–7.8 years) with pre-treatment (18)F-FDG PET/CT from September 2020 to September 2022 in Nuclear Medicine Department, Beijing friendship hospital, Capital Medical University, Beijing, China. These patients were then all admitted to the hospital and diagnosed with LCH by biopsy, in Hematology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China. Five metabolism parameters of (18)F-FDG PET/CT were analyzed, including maximum standardized uptake, tumor-to-normal liver standard uptake value ratio, tumor-to-normal bone marrow standard uptake value ratio, sum of metabolic tumor volume (sMTV), and sum of total lesion glycolysis (sTLG) of all lesions. Patients were followed up for at least 1 year or until disease progression/relapse. Univariate and multivariate analyses of progression-free survival was performed. RESULTS: During follow-up, 11 (29.7%) patients had disease progression/relapse. Univariate analysis revealed that the risk organ involvement, the treatment response at the 5(th) or 11(th) week, pre-treatment sMTV, and sTLG were significantly associated with progression-free survival (P=0.024, 0.018, 0.006, 0.006, and 0.042, respectively). Multivariate COX analysis revealed that non-response at the 11(th) week, pre-treatment sMTV >32.55 g/cm(3), and sTLG >98.86 g (P=0.002, 0.020, 0.026, respectively) were risk factors for progression-free survival. CONCLUSIONS: The baseline metabolism parameters of (18)F-FDG PET/CT could be promising imaging biomarkers for predicting prognosis in children with LCH. |
format | Online Article Text |
id | pubmed-10498231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-104982312023-09-14 The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis Lu, Xia Wei, Ang Wang, Guanyun Du, Junye Feng, Lijuan Ou, Wenxin Wang, Tianyou Wang, Wei Li, Jixia Zhang, Mingyu Zhang, Rui Yang, Jigang Quant Imaging Med Surg Original Article BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare myeloid precursor cell inflammatory neoplasia, which agonizes, maims, and even kills patients. Although clinical outcomes have steadily improved over the past decades, the progression/relapse rate of LCH remains high. The purpose of this study was to evaluate the prognostic value of the pre-treatment metabolism parameters of baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F‑FDG PET/CT) in children with LCH. METHODS: This cross-sectional study retrospectively and consecutively included 37 children (24 males and 13 females; median age, 5.1 years; range, 2.4–7.8 years) with pre-treatment (18)F-FDG PET/CT from September 2020 to September 2022 in Nuclear Medicine Department, Beijing friendship hospital, Capital Medical University, Beijing, China. These patients were then all admitted to the hospital and diagnosed with LCH by biopsy, in Hematology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China. Five metabolism parameters of (18)F-FDG PET/CT were analyzed, including maximum standardized uptake, tumor-to-normal liver standard uptake value ratio, tumor-to-normal bone marrow standard uptake value ratio, sum of metabolic tumor volume (sMTV), and sum of total lesion glycolysis (sTLG) of all lesions. Patients were followed up for at least 1 year or until disease progression/relapse. Univariate and multivariate analyses of progression-free survival was performed. RESULTS: During follow-up, 11 (29.7%) patients had disease progression/relapse. Univariate analysis revealed that the risk organ involvement, the treatment response at the 5(th) or 11(th) week, pre-treatment sMTV, and sTLG were significantly associated with progression-free survival (P=0.024, 0.018, 0.006, 0.006, and 0.042, respectively). Multivariate COX analysis revealed that non-response at the 11(th) week, pre-treatment sMTV >32.55 g/cm(3), and sTLG >98.86 g (P=0.002, 0.020, 0.026, respectively) were risk factors for progression-free survival. CONCLUSIONS: The baseline metabolism parameters of (18)F-FDG PET/CT could be promising imaging biomarkers for predicting prognosis in children with LCH. AME Publishing Company 2023-08-04 2023-09-01 /pmc/articles/PMC10498231/ /pubmed/37711802 http://dx.doi.org/10.21037/qims-23-290 Text en 2023 Quantitative Imaging in Medicine and Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Lu, Xia Wei, Ang Wang, Guanyun Du, Junye Feng, Lijuan Ou, Wenxin Wang, Tianyou Wang, Wei Li, Jixia Zhang, Mingyu Zhang, Rui Yang, Jigang The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis |
title | The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis |
title_full | The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis |
title_fullStr | The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis |
title_full_unstemmed | The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis |
title_short | The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis |
title_sort | baseline metabolism parameters of (18)f‑fdg pet/ct as promising prognostic biomarkers in pediatric langerhans cell histiocytosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498231/ https://www.ncbi.nlm.nih.gov/pubmed/37711802 http://dx.doi.org/10.21037/qims-23-290 |
work_keys_str_mv | AT luxia thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT weiang thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT wangguanyun thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT dujunye thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT fenglijuan thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT ouwenxin thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT wangtianyou thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT wangwei thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT lijixia thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT zhangmingyu thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT zhangrui thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT yangjigang thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT luxia baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT weiang baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT wangguanyun baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT dujunye baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT fenglijuan baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT ouwenxin baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT wangtianyou baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT wangwei baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT lijixia baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT zhangmingyu baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT zhangrui baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis AT yangjigang baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis |